A Study of Universal CD19-Targeted UCAR-NK Cells Combined With HSCT for B Cell Hematologic Malignancies
Study Details
Study Description
Brief Summary
It is a single-center, open-labeled, single-arm, non-randomized investigator-initiated trial evaluating the efficacy and safety of anti-CD19 universal CAR-NK(UCAR-NK) cells therapy combined with HSCT for B cell hematologic malignancies.
| Condition or Disease | Intervention/Treatment | Phase |
|---|---|---|
|
Phase 1/Phase 2 |
Detailed Description
Who can participate? Patients who were diagnosed with B cell hematologic malignancies and tumor cells expressing CD19.
How to conduct this study? This study is an interventional clinical study. The intervention in the trial is anti-CD19 UCAR-NK cells, which belong to chimeric antigen receptor modified NK cells. The administration time is 1-7 days after hematopoietic stem cell infusion. Patients were then evaluated for long-term efficacy and safety until 2 years after UCAR-NK cells infusion.
What are the possible benefits and risks of participating? Benefits: The Dual effect of anti-tumor and anti-infection of NK cells may be used to promote the engraftment of hematopoietic stem cell and better disease control.
Risks: Subjects may have adverse reactions to the treatment. These adverse reactions may include abnormal liver injury, fever, thrombocytopenia, thrombotic microangiopathy, and possibly other unknown adverse reactions.
Study Design
Arms and Interventions
| Arm | Intervention/Treatment |
|---|---|
| Experimental: Target CD19 UCAR-NK cells Subjects who meet the enrollment conditions will receive intravenous infusion of anti-CD19 UCAR-NK Cells within 1 week after hematopoietic stem cell infusion. |
Biological: Anti-CD19 UCAR-NK cells
The trial includes two portions. The first portion is a"3+3"dose escalation study, in which three dose groups are set three different dose levels of UCAR-NK cells:Dose level one: 5-10×10^6/kg; Dose level two:1-2×10^7/kg; Dose level three:2-5×10^7/kg.
|
Outcome Measures
Primary Outcome Measures
- Incidence of adverse events(AE) after infusion [Up to 12 months after infusion]
The frequency, severity, and laboratory findings of all adverse events/serious adverse events are included. Description, time, classification, and outcome of AE events resulted from the investigational medical product, delivery method, or emergency measures will be recorded in the case report form.
Secondary Outcome Measures
- Granulocyte implantation time [Up to 1 month after infusion]
Time from hematopoietic stem cell transfusion to peripheral blood granulocyte count >0.5×10^9/L for 3 consecutive days.
- Platelet implantation time [Up to 1 month after infusion]
Time from hematopoietic stem cell transfusion to peripheral blood platelet count >20×10^9/L for 7 consecutive days.
- Red blood cell implantation time [Up to 1 month after infusion]
Time from hematopoietic stem cell transfusion to peripheral blood hemoglobin count >70g/L.
- Duration of remission (DOR) [Up to 24 weeks after infusion]
Duration of remission (DOR) refers to the time from the first assessment of complete response(CR) or partial response(PR) of the tumor to the first assessment of disease recurrence or progression or death from any cause.
- Disease control rate (DCR) [Up to 24 weeks after infusion]
Disease control rate (DCR) are defined as the percentage of patients who have achieved complete response, partial response or stable disease to a therapeutic intervention in clinical trials of anticancer agents.
- Overall survival (OS) [Up to 24 weeks after infusion]
Overall survival (OS) refers to the time from the time the patient received an infusion of CAR-NK cells until death (from any cause).
- Progression-free survival (PFS) [Up to 24 weeks after infusion]
Progression-free survival (PFS) refers to the time from the start of treatment with CAR-NK cells to the first progression of disease or death from any cause.
Eligibility Criteria
Criteria
Inclusion Criteria:
-
Patients with indications for hematopoietic stem cell transplantation;
-
Age ≤75 years old;
-
Confirmed B-cell tumor and tumor cells expressing CD19；
-
Expected survival time >12 weeks;
-
Eastern cooperative oncology group (ECOG) score is 0-2;
-
Adequate liver , kidney and cardiopulmonary function;
-
Willingness to complete the informed consent process and to comply with study procedures and visit schedule.
Exclusion Criteria:
-
Had received NK cell therapy or other genetically modified cell therapy within 1 year before screening;
-
At least 14 days or at least 5 half-lives of antitumor therapy had elapsed before screening;
-
Patients who had undergone hematopoietic stem cell transplantation (ASCT), allogeneic hematopoietic stem cell transplantation (HSCT), or solid organ transplantation within 12 weeks before screening; Grade 2 or higher graft versus host disease(GVHD) requiring immunosuppressive therapy occurred within 2 weeks before screening;
-
Patients with atrial or ventricular lymphoma or need urgent treatment due to tumor mass such as intestinal obstruction or vascular compression;
-
Have received live attenuated vaccine within 6 weeks before rinsing;
-
Had a cerebrovascular accident or seizure within 6 months before screening;
-
History of deep venous thrombosis or pulmonary embolism within 6 months before screening;
-
A history of myocardial infarction, bypass or stent bypass, unstable angina, or other clinically significant heart disease within 12 months prior to screening;
-
Previous history of Alzheimer's disease;
-
Autoimmune diseases leading to end-organ damage or requiring systemic immunosuppression (e.g. Crohns, rheumatoid arthritis, systemic lupus erythematosus) within 2 years prior to screening;
-
There are uncontrollable infections;
-
Women who are pregnant or breastfeeding; Or women of childbearing age who have positive pregnancy tests during the screening period; Male or female patients who did not wish to use contraception from the time of signing the informed consent to 1 year after receiving the NK cell infusion;
-
Conditions that other researchers deemed inappropriate for participating in the study.
Contacts and Locations
Locations
| Site | City | State | Country | Postal Code | |
|---|---|---|---|---|---|
| 1 | 920th Hospital of Joint Logistics Support Force of People's Liberation Army of China | Kunming | Yunnan | China | 650000 |
Sponsors and Collaborators
- 920th Hospital of Joint Logistics Support Force of People's Liberation Army of China
Investigators
- Principal Investigator: Sanbin Wang, MD, 920th Hospital of Joint Logistics Support Force of People's Liberation Army of China
Study Documents (Full-Text)
None provided.More Information
Publications
None provided.- KM-011